Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Theresa Lee

Gastroenterology Lone Tree, CO Medical Doctor

NPI 1457676645 CMS profile 689935

10103 Ridgegate Pkwy Ste 312, Lone Tree, CO 80124

Open in the dashboard

General payments

$9,154

108 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Theresa Lee of Lone Tree, CO is reported in the CMS Open Payments database as having received $9,154 across 108 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $509 20
2024 General $596 12
2023 General $4,387 20
2022 General $3,183 24
2021 General $103 6
2020 General $128 9
2019 General $248 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Theresa Lee
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Theresa Lee were reported at $509. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Theresa Lee Gastroenterology median Middle half National median
2019 $248 $417 $126–$1,100 $163
2020 $128 $224 $74–$624 $114
2021 $103 $352 $106–$1,054 $132
2022 $3,183 $448 $129–$1,270 $149
2023 $4,387 $533 $150–$1,390 $160
2024 $596 $605 $160–$1,606 $164
2025 $509 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. CapsoVision, Inc. $6,600 4 payments
  2. AbbVie, Inc. $1,115 32 payments
  3. Celgene Corporation $295 19 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $261 9 payments
  5. Pfizer Inc. $182 12 payments
  6. Lilly USA, LLC $123 1 payment
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $91 5 payments
  8. Axonics Modulation Technologies, Inc. $54 1 payment
  9. Ironwood Pharmaceuticals, Inc $53 3 payments
  10. Madrigal Pharmaceuticals $52 2 payments
  11. Other $328 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $6,600 4 payments
  2. Food and Beverage $2,546 103 payments
  3. Education $8 1 payment
Products named General payments · program years 2019–2025
  1. CapsoCam Plus $3,800 2 payments
  2. CapsoCam Colon $2,800 2 payments
  3. SKYRIZI Immunology $507 13 payments
  4. RINVOQ $341 17 payments
  5. ZEPOSIA $295 19 payments
  6. XELJANZ $182 12 payments
  7. SKYRIZI Immunology $155 12 payments
  8. ENTYVIO $139 2 payments
  9. OMVOH $123 1 payment
  10. XIFAXAN $91 5 payments
  11. Other $801 44 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

267

Median for Gastroenterology: 569

Drug cost

$95,793

Median for Gastroenterology: $104,976

Branded share of claims

38.6%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xeljanz Tofacitinib Citrate Brand 12 $66,881
Linzess Linaclotide Brand 15 $12,578
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 65 $10,695
Colesevelam Hcl Generic 18 $2,238
Colestipol Hcl Generic 21 $1,486
Omeprazole Generic 73 $1,293
Pantoprazole Sodium Generic 24 $222
Ondansetron Odt Ondansetron Brand 11 $211
Prednisone Generic 17 $124
Amitriptyline Hcl Generic 11 $65

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$128,918

Of which drugs: $100,337

Medicare patients

145

Average age 72

Services billed

5,987

99 women, 46 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 55%
Arthritis 52%
Ischemic heart disease 23%
Osteoporosis 23%
Depression 22%
Cancer 18%
Diabetes 17%
Chronic kidney disease 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vedolizumab, 1 mg J3380 Office 13 4,800 $78,107

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $132
$132 — —
OMVOH
  • Lilly USA, LLC $123
$123 — —
RESMETIROM
  • Madrigal Pharmaceuticals $33
$33 — —
IBSRELA
  • Ardelyx, Inc. $22
$22 — —
Sucraid
  • QOL Medical, LLC $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

108 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record